Rossdorf, Germany

Michael Klockow


Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 130(Granted Patents)


Location History:

  • Darmstadt, DE (1976)
  • Ro dorf, DE (1991)
  • Rossdorf, DE (1981 - 2000)

Company Filing History:


Years Active: 1976-2000

Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Michael Klockow

Introduction

Michael Klockow is a notable inventor based in Rossdorf, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that exhibit therapeutic effects for various disorders. With a total of 12 patents to his name, Klockow's work has had a considerable impact on medical science.

Latest Patents

Among his latest patents, Klockow has developed Arylalkyl-thiadiazinones, which are derivatives that exhibit phosphodiesterase IV inhibition. These compounds can be utilized in the therapy of asthmatic disorders. Another significant patent involves 4-(arylaminomethylene)-2,4-dihydro-3-pyrazolones, which are 5-pyrazolinone derivatives that serve as selective inhibitors of cGMP-specific phosphodiesterase. These compounds are recognized for their potential as pharmaceutically active agents.

Career Highlights

Throughout his career, Klockow has worked with prominent organizations, including Merck Patent Gesellschaft mit beschränkter Haftung. His expertise in pharmaceutical innovation has positioned him as a key figure in the development of new therapeutic agents.

Collaborations

Klockow has collaborated with notable colleagues such as Rochus Jonas and Michael Wolf. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Michael Klockow's innovative work in pharmaceuticals has led to the creation of valuable therapeutic compounds. His contributions continue to influence the field and provide potential solutions for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…